Search results for " Good"

showing 10 items of 5326 documents

Estrogen Signaling in Bystander Foxp3 neg CD4 + T Cells Suppresses Cognate Th17 Differentiation in Trans and Protects from Central Nervous System Aut…

2018

Abstract 17β-Estradiol (E2) suppresses the development of experimental autoimmune encephalomyelitis (EAE) through estrogen receptor (ER) α, yet the cellular targets remain elusive. We have used an adoptive transfer model of myelin oligodendrocyte glycoprotein–specific CD4+ T cells from 2D2 TCR transgenic mice. We show that in the recipient mice, ERα expression in bystander CD4+ T cells, rather than in cognate 2D2 T cells, is required for the inhibition of Th17 cell differentiation by E2. Coadministration of estrogen-primed WT, but not ERα-deficient CD4+ T cells, with naive 2D2 T cells lacking ERα inhibited the development of Th17 cell–mediated EAE. Suppression of Th17 cells and protection f…

0301 basic medicineAdoptive cell transferCell growthChemistryCellular differentiation[SDV]Life Sciences [q-bio]ImmunologyExperimental autoimmune encephalomyelitisEstrogen receptorFOXP3medicine.diseaseOligodendrocyte3. Good healthCell biology03 medical and health sciences030104 developmental biology0302 clinical medicinemedicine.anatomical_structureBystander effectmedicineImmunology and AllergyComputingMilieux_MISCELLANEOUS030215 immunology
researchProduct

Phase I Study of the Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitor Navoximod (GDC-0919) Administered with PD-L1 Inhibitor (Atezolizumab) in Advanced…

2019

Abstract Purpose: IDO1 induces immune suppression in T cells through l-tryptophan (Trp) depletion and kynurenine (Kyn) accumulation in the local tumor microenvironment, suppressing effector T cells and hyperactivating regulatory T cells (Treg). Navoximod is an investigational small-molecule inhibitor of IDO1. This phase I study evaluated safety, tolerability, pharmacokinetics, and pharmacodynamics of navoximod in combination with atezolizumab, a PD-L1 inhibitor, in patients with advanced cancer. Patients and Methods: The study consisted of a 3+3 dose-escalation stage (n = 66) and a tumor-specific expansion stage (n = 92). Navoximod was given orally every 12 hours continuously for 21 consecu…

0301 basic medicineAdultCancer ResearchIndoles[SDV]Life Sciences [q-bio][SDV.BC]Life Sciences [q-bio]/Cellular BiologyPharmacologyAntibodies Monoclonal HumanizedArticleB7-H1 Antigen03 medical and health sciences0302 clinical medicinePharmacokineticsAtezolizumabRenal cell carcinomaNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsmedicineBiomarkers TumorHumansIndoleamine-Pyrrole 23-DioxygenaseNeoplasm MetastasisAgedNeoplasm StagingAged 80 and overBladder cancerbusiness.industryMelanomaImidazolesMiddle Agedmedicine.diseaseMagnetic Resonance Imaging3. Good health030104 developmental biologyTreatment OutcomeOncologyTolerability030220 oncology & carcinogenesisPharmacodynamicsPD-L1 inhibitorbusinessTomography X-Ray Computed
researchProduct

Serum Lycopene Concentrations and Associations with Clinical Outcomes in a Cohort of Maternal-Infant Dyads.

2018

Oxidative stress has been associated with adverse neonatal outcomes, and many carotenoids, including lycopene, potentially have antioxidant properties. The objective of this analysis was to explore the associations between serum lycopene concentrations, including lycopene isomers, and maternal-newborn outcomes. Maternal and cord blood samples were collected in 180 mother-infant pairs. Serum of total lycopene as well as the cis- and trans-isomers concentrations were measured using HPLC (High Performance Liquid Chromatography). Descriptive statistics were calculated; Spearman coefficients were used to assess correlations between maternal and cord concentrations. The relationship between lycop…

0301 basic medicineAdultCordBirth weightPhysiologyMotherslcsh:TX341-641AntioxidantsArticlelaw.inventionCohort Studies03 medical and health scienceschemistry.chemical_compoundYoung Adult0302 clinical medicinelawPregnancyIntensive Care Units Neonatalcarotenoid; lycopene; pregnancy; neonatal growthmedicineBirth WeightHumansPregnancyRespiratory Distress Syndrome Newborn030219 obstetrics & reproductive medicine030109 nutrition & dieteticsNutrition and DieteticsRespiratory distressbusiness.industryInfant NewbornInfantmedicine.diseaseFetal BloodlycopeneIntensive care unitCarotenoidsLycopenecarotenoid3. Good healthDietOxidative Stresschemistryneonatal growthCord bloodCohortFemalebusinesslcsh:Nutrition. Foods and food supplyFood ScienceNutrients
researchProduct

Assessment of liver fibrosis progression and regression by a serological collagen turnover profile

2018

There is a need for noninvasive biomarkers that can identify patients with progressive liver fibrosis and monitor response to antifibrotic therapy. An equally important need is identification of patients with spontaneous fibrosis regression, since they may not need treatment nor be included in clinical studies with fibrosis as end point. Circulating biomarkers, originating from defined fragments of the scar tissue itself, may serve as valuable tools for this aspect of precision medicine. We investigated a panel of serological collagen formation and degradation markers to identify patients likely to regress or progress in absence of a therapeutic intervention. Plasma samples from patients wi…

0301 basic medicineAdultLiver CirrhosisMalePathologymedicine.medical_specialtyPhysiologyLiver fibrosisBiopsySerology03 medical and health sciences0302 clinical medicinePhysiology (medical)medicineHumansBasement membraneHepatologybusiness.industryGastroenterologyMiddle AgedFibrosis3. Good healthProcollagen peptidase030104 developmental biologymedicine.anatomical_structurePhenotypeDisease ProgressionBiomarker (medicine)030211 gastroenterology & hepatologyFemaleCollagenbusinessBiomarkersAmerican Journal of Physiology-Gastrointestinal and Liver Physiology
researchProduct

Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denm…

2016

BACKGROUND: The aim of the present EURECCA international comparison is to compare adjuvant chemotherapy and relative survival of patients with stage II colon cancer between European countries.METHODS: Population-based national cohort data (2004-2009) from the Netherlands (NL), Denmark (DK), Sweden (SE), England (ENG), Ireland (IE), and Belgium (BE) were obtained, as well as single-centre data from Lithuania. All surgically treated patients with stage II colon cancer were included. The proportion of patients receiving adjuvant chemotherapy was calculated and compared between countries. Besides, relative survival was calculated and compared between countries.RESULTS: Overall, 59,154 patients …

0301 basic medicineAdultMaleCancer Researchmedicine.medical_specialtyAdjuvant chemotherapyColorectal cancerPopulationDiseasePopulation-basedStage II03 medical and health sciences0302 clinical medicinePharmacotherapySDG 3 - Good Health and Well-beingInternal medicineAntineoplastic Combined Chemotherapy ProtocolsJournal ArticlemedicineHumansStage (cooking)educationInternational comparisonAgedGynecologyeducation.field_of_studyRelative survivalbusiness.industryResearch Support Non-U.S. Gov'tMiddle Agedmedicine.diseaseSurvival AnalysisColon cancerAdjuvant chemotherapyEurope030104 developmental biologyLogistic ModelsOncologyChemotherapy Adjuvant030220 oncology & carcinogenesisColonic NeoplasmsSurgeryFemalebusinessStage ii colon cancerEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Therapeutic drug monitoring as a tool to optimize 5-FU-based chemotherapy in gastrointestinal cancer patients older than 75 years.

2019

Abstract Aims Most clinical trials exclude elderly people, leading to a limited understanding of the benefit-to-risk ratio in this population. Despite existing data regarding the oncological management of elderly receiving fluorouracil (5-FU)-based regimen, our objective was to investigate 5-FU exposure/toxicity relationship in patients ≥75 years and compare the effectiveness of 5-FU therapeutic drug monitoring between elderly and younger patients. Methods Hundred fifty-four patients (31 of whom are older than 75 years) with gastrointestinal cancers, who were to receive 5-FU–based regimens, were included in our study. At cycle 1 (C1), the 5-FU dose was calculated using patient's body surfac…

0301 basic medicineAdultMaleCancer Researchmedicine.medical_specialty[SDV]Life Sciences [q-bio]PopulationAntineoplastic Agents03 medical and health sciences0302 clinical medicineInternal medicinemedicineHumansGastrointestinal cancereducationAgedGastrointestinal NeoplasmsRetrospective StudiesBody surface areaAged 80 and overeducation.field_of_studymedicine.diagnostic_testDose-Response Relationship Drugbusiness.industryArea under the curveMiddle Agedmedicine.disease3. Good healthClinical trialRegimen030104 developmental biologyOncologyTolerabilityTherapeutic drug monitoring030220 oncology & carcinogenesisFemaleFluorouracilDrug MonitoringbusinessEuropean journal of cancer (Oxford, England : 1990)
researchProduct

Rescuing Over-activated Microglia Restores Cognitive Performance in Juvenile Animals of the Dp(16) Mouse Model of Down Syndrome.

2020

Microglia are brain-resident immune cells and regulate mechanisms essential for cognitive functions. Down syndrome (DS), the most frequent cause of genetic intellectual disability, is caused by a supernumerary chromosome 21, containing also genes related to the immune system. In the hippocampus of the Dp(16) mouse model of DS and DS individuals, we found activated microglia, as assessed by their morphology; activation markers; and, for DS mice, electrophysiological profile. Accordingly, we found increased pro-inflammatory cytokine levels and altered interferon signaling in Dp(16) hippocampi. DS mice also showed decreased spine density and activity of hippocampal neurons and hippocampus-depe…

0301 basic medicineAdultMaleDown syndromeDendritic spinemedicine.medical_treatmentAminopyridinesMice TransgenicHippocampal formationHippocampus03 medical and health sciencesMice0302 clinical medicineImmune systemCognitionMedicineHippocampus (mythology)AnimalsHumansPyrrolesNeuroinflammationMicrogliabusiness.industryGeneral NeuroscienceAnti-Inflammatory Agents Non-SteroidalAge Factorsmedicine.disease3. Good healthMice Inbred C57BLDisease Models Animal030104 developmental biologymedicine.anatomical_structureCytokinenervous systemFemaleMicrogliaDown SyndromebusinessNeuroscience030217 neurology & neurosurgeryNeuron
researchProduct

Reducing diagnostic turnaround times of exome sequencing for families requiring timely diagnoses

2017

IF 2.137; International audience; BACKGROUND AND OBJECTIVE:Whole-exome sequencing (WES) has now entered medical practice with powerful applications in the diagnosis of rare Mendelian disorders. Although the usefulness and cost-effectiveness of WES have been widely demonstrated, it is essential to reduce the diagnostic turnaround time to make WES a first-line procedure. Since 2011, the automation of laboratory procedures and advances in sequencing chemistry have made it possible to carry out diagnostic whole genome sequencing from the blood sample to molecular diagnosis of suspected genetic disorders within 50 h. Taking advantage of these advances, the main objective of the study was to impr…

0301 basic medicineAdultMaleExome sequencingmedicine.medical_specialtyTime FactorsAdolescentGenetic counselingBioinformaticsTurnaround timeSensitivity and SpecificityUndiagnosed genetic conditions03 medical and health sciencesGeneticsmedicineHumansExomeGenetic TestingMedical diagnosisIntensive care medicineChildExomeGenetics (clinical)Exome sequencingGenetic testingWhole genome sequencing[SDV.GEN]Life Sciences [q-bio]/Geneticsmedicine.diagnostic_testbusiness.industryInfant NewbornInfantGeneral MedicineSequence Analysis DNADiagnostic turnaround time3. Good healthClinical trial030104 developmental biologyEarly DiagnosisChild PreschoolFemalebusiness[ SDV.GEN ] Life Sciences [q-bio]/Genetics
researchProduct

Antibodies against Lewis antigens inhibit the binding of human norovirus GII.4 virus-like particles to saliva but not to intestinal Caco-2 cells.

2016

BACKGROUND: Human noroviruses (NoVs) are the main cause of gastroenteritis worldwide. The most commonly detected NoV strains belong to the genetically diverse GII.4 genotype, with new pandemic variants emerging periodically. Despite extensive efforts, NoV investigation has been hampered by the lack of an effective in vitro cell culture system. However, NoV-derived recombinant virus-like particles (VLPs) resembling empty capsids are good surrogates for analysing NoV antigenicity and virus-ligand interactions. NoV VLPs have been reported to bind to histo-blood group antigens (HBGAs). We have analysed the ability of NoV VLPs derived from GI.1 genotype and from three GII.4 genotype variants, GI…

0301 basic medicineAdultMaleSalivaAntigenicitymedicine.drug_classSwinevirusesVirus AttachmentMonoclonal antibodyImmunofluorescenceVirusMicrobiology03 medical and health sciencesLewis Blood Group Antigensfluids and secretionsAntigenstomatognathic systemGII.4 genotypeHisto-blood group antigens (HBGAs)VirologymedicineAnimalsHumansChildSalivaAutoantibodiesbiologymedicine.diagnostic_testResearchMucinNorovirusvirus diseasesEpithelial CellsMiddle AgedVirology3. Good healthVirus-like particles (VLPs)030104 developmental biologyInfectious DiseasesHuman norovirus (NoV)Host-Pathogen Interactionsbiology.proteinReceptors VirusReceptor bindingFemaleAntibodyCaco-2 Cells
researchProduct

Altered distribution and function of splenic innate lymphoid cells in adult chronic immune thrombocytopenia

2018

IF 7.607; International audience; Innate lymphoid cells (ILCs) have been characterized as innate immune cells capable to modulate the immune response in the mucosae. Human ILCs have been rarely described in secondary lymphoid organs except in tonsils. Moreover, their function and phenotype in human secondary lymphoid organs during autoimmune diseases have never been studied. We took advantage of splenectomy as a treatment of immune thrombocytopenia (ITP) to describe and compare splenic ILC from 18 ITP patients to 11 controls. We first confirmed that ILC3 represented the most abundant ILC subset in human non-inflamed spleens, accounting for 90% of total ILC, and that they were mostly constit…

0301 basic medicineAdultMalemedicine.medical_treatmentImmunologySplenectomyGene ExpressionSpleenInnate lymphoid cells[SDV.CAN]Life Sciences [q-bio]/Cancer03 medical and health sciencesInterferon-gamma0302 clinical medicineImmune systemhemic and lymphatic diseasesmedicineImmunology and AllergyHumansLymphocyte CountLymphocytesskin and connective tissue diseasesAutoimmune diseasePurpura Thrombocytopenic IdiopathicInnate immune systemNatural Cytotoxicity Triggering Receptor 2business.industryMacrophagesInnate lymphoid cellInterleukin-2 Receptor alpha SubunitGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationMiddle Agedmedicine.diseasePathophysiologyImmunity Innate3. Good healthImmune thrombocytopenia030104 developmental biologymedicine.anatomical_structureLymphatic systemCase-Control StudiesImmunologySplenectomyFemalebusinessSpleen030215 immunology
researchProduct